Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03991780 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

Study acronym: FOSTAMR
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 10 to confirmed 8 · Primary completion date changed from estimate of Jul 31, 2024 to Apr 5, 2023 · Completion date: Jul 31, 2024 to Oct 15, 2025 · 1 morev4 Show 4 more changesShow less
    • Enrollment target: estimated 10 to confirmed 8
    • Primary completion date changed from estimate of Jul 31, 2024 to Apr 5, 2023
    • Completion date: Jul 31, 2024 to Oct 15, 2025
    • Site details revised
  2. Primary and study completion dates: Feb 2021 to Jul 31, 2024v3
  3. Secondary endpoints revised (3) Study description revisedv2 Show 1 more changeShow less
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation
Trial Details
NCT Number NCT03991780
Lead Sponsor Imperial College London
Conditions Renal Transplant Rejection
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov